Pfizer, BioNTech agree to sell 40M vaccine doses to COVAX

Friday, 22. January 2021 18:15

Pfizer and BioNTech announced on Friday they reached an agreement to sell 40 million doses of their coronavirus vaccine to COVAX, the global initiative to ensure equitable access to COVID-19 vaccines for all countries.

The companies noted the first deliveries under the deal are expected to take place in the first quarter of 2021, "subject to the negotiation and execution of supply agreements under the COVAX Facility structure."

Pfizer and BioNTech added they will provide the vaccine at a not-for-profit price to COVAX for the 92 poorest countries.

Related Links: 
Breaking the News / NP